Epoetin alfa biosimilar - Biosidus

Drug Profile

Epoetin alfa biosimilar - Biosidus

Alternative Names: Epoimmun™; Epoyet™; Hemax (Epoetin alfa); Hypercrit; Zyrop™

Latest Information Update: 20 Sep 2013

Price : $50

At a glance

  • Originator Biosidus S.A.
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 01 Jul 2013 Launched for Anaemia in China (SC)
  • 29 Apr 2013 Launched for Anaemia in Thailand (SC)
  • 07 Dec 2011 Launched for Anaemia in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top